Oxidized phospholipids on apoB-100-containing lipoproteins: A biomarker predicting cardiovascular disease and cardiovascular events

Biomarkers in Medicine

Volumn 5, Issue 5, 2011, Pages 673-694

  Taleb, Adam ^a   Witztum, Joseph L ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

atherosclerosis; biomarker; lipoproteins; outcome; oxidation; oxidative stress; oxidized phospholipid

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN B100; LIPOPROTEIN; LIPOPROTEIN A; OXIDIZED PHOSPHOLIPID; PHOSPHOLIPID; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; CAROTID ARTERY DISEASE; CORONARY ARTERY DISEASE; DEATH; DISEASE ASSOCIATION; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL ARTERY DISEASE; FRAMINGHAM RISK SCORE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; NONHUMAN; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PREDICTION; PREDICTIVE VALUE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REVIEW; RISK FACTOR; STROKE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN B-100; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; LIPOPROTEIN(A); OXIDATION-REDUCTION; PHOSPHOLIPIDS; PREDICTIVE VALUE OF TESTS; RISK FACTORS;

EID: 80054814637     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.60     Document Type: Review

References (75)

1. Glass CK, Witztum JL. Atherosclerosis. The road ahead. Cell 104(4), 503-516 (2001).
2. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat. Rev. Cardiol. 8(4), 222-332 (2011).
3. Esterbauer H, Gebicki J, Puhl H, Ju¨rgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Rad. Biol. Med. 13(4), 341-390 (1992).
4. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320(14), 915-924 (1989). (Pubitemid 19101597)
5. Nishi K, Itabe H, Uno M, et al. Oxidized LDL in carotid plaques and plasma associates with plaque instability. Arterioscler. Thromb. Vasc. Biol. 22(10), 1649-1654 (2002).
6. Seimon TA, Nadolski MJ, Liao X, et al. Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab. 12(5), 467-482 (2010).
7. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat. Cell Biol. 13(3), 184-190 (2011).
8. Salonen JT, Yl-Herttuala S, Yamamoto R, et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 339(8798), 883-887 (1992).
9. Palinski W, Rosenfeld ME, Ylα-Herttuala S, et al. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl Acad. Sci. USA 86(4), 1372-1376 (1989). (Pubitemid 19061548)
10. Palinski W, Ord VA, Plump AS, Breslow JL, Steinberg D, Witztum JL. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler. Thromb. 14(4), 605-616 (1994).
11. Berliner JA, Leitinger N, Tsimikas S. The role of oxidized phospholipids in atherosclerosis. J. Lipid Res. 50(Suppl.), S207-S212 (2009).
12. Bochkov VN, Oskolkova OV, Birukov KG, Levonen AL, Binder CJ, Stockl J. Generation and biological activities of oxidized phospholipids. Antioxid. Redox Signal. 12(8), 1009-1059 (2010).
13. Greenberg ME, Li XM, Gugiu BG, et al. The lipid whisker model of the structure of oxidized cell membranes. J. Biol. Chem. 283(4), 2385-2396 (2008).
14. Ravandi A, Harkewicz R, Leibundgut G, et al. Identification of oxidized phospholipids and cholesteryl esters in embolic protection devices post percutaneous coronary, carotid and peripheral interventions in humans. Arterioscler. Thromb. Vasc. Biol. P385 (2011).
15. Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002). (Pubitemid 36019640)
16. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J. Clin. Invest. 103(1), 117-128 (1999). (Pubitemid 29031170)
17. Shaw PX, Horkko S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J. Clin. Invest. 105(12), 1731-1740 (2000). (Pubitemid 30421754)
18. Friedman P, Horkko S, Steinberg D, Witztum JL, Dennis EA. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J. Biol. Chem. 277(9), 7010-7020 (2002). (Pubitemid 34953088)
19. Briles DE, Forman C, Hudak S, Claflin JL. Anti-phosphorylcholine antibodies of the T15 idiotype are optimally protective against Streptococcus pneumoniae. J. Exp. Med. 156(4), 1177-1185 (1982). (Pubitemid 12036279)
20. Imai Y, Kuba K, Neely GG, et al. Identifof oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury. Cell 133(2), 235-249 (2008). (Pubitemid 351512299)
21. Cruz D, Watson AD, Miller CS, et al. Host-derived oxidized phospholipids and HDL regulate innate immunity in human leprosy. J. Clin. Invest. 118(8), 2917-2928 (2008).
22. Chang MK, Bergmark C, Laurila A, et al. Monoclonal antibodies against oxidized low-density lipoprotein bind to apoptotic cells and inhibit their phagocytosis by elicited macrophages: evidence that oxidation-specific epitopes mediate macrophage recognition. Proc. Natl Acad. Sci. USA 96(11), 6353-6358 (1999). (Pubitemid 29256669)
23. Ogden CA, Kowalewski R, Peng Y, Montenegro V, Elkon KB. IGM is required for efficient complement mediated phagocytosis of apoptotic cells in vivo. Autoimmunity 38(4), 259-264 (2005). (Pubitemid 40974955)
24. Binder CJ, Horkko S, Dewan A, et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 9(6), 736-743 (2003). (Pubitemid 36749223)
25. Hartvigsen K, Chou MY, Hansen LF, et al. The role of innate immunity in atherogenesis. J. Lipid Res. 50(Suppl.), S388-S393 (2009).
26. Miller YI, Choi SH, Wiesner P, et al. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res. 108(2), 235-248 (2011).
27. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J. Am. Coll. Cardiol. 41(3), 360-370 (2003). (Pubitemid 36164488)
28. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J. Am. Coll. Cardiol. 47(11), 2219-2228 (2006). (Pubitemid 43795077)
29. Young SG, Smith RS, Hogle DM, Curtiss LK, Witztum JL. Two new monoclonal antibody-based enzyme-linked assays of apolipoprotein B. Clin. Chem. 32(8), 1484-1490 (1986). (Pubitemid 17027765)
30. Fraley AE, Tsimikas S. Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. Curr. Opin. Lipidol. 17(5), 502-509 (2006). (Pubitemid 44372680)
31. Tsimikas S, Witztum JL. The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. Curr. Opin. Lipidol. 19(4), 369-377 (2008).
32. Young SG, Witztum JL, Casal DC, Curtiss LK, Bernstein S. Conservation of the low density lipoprotein receptor-binding domain of apoprotein B. Demonstration by a new monoclonal antibody, MB47. Arteriosclerosis 6(2), 178-188 (1986). (Pubitemid 16024127)
33. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 109(25), 3164-3170 (2004).
34. Rhoads GG, Dahlen G, Berg K, Morton NE, Dannenberg AL. Lp(a) lipoprotein as a risk factor for myocardial infarction. JAMA 256(18), 2540-2544 (1986). (Pubitemid 17025291)
35. Seed M, Hoppichler F, Reaveley D, et al. Relation of serum lipoprotein(a) concentration and apolipoprotein(a) phenotype to coronary heart disease in patients with familial hypercholesterolemia. N. Engl. J. Med. 322(21), 1494-1499 (1990). (Pubitemid 20179863)
36. Dangas G, Ambrose JA, Dagate DJ, et al. Correlation of serum lipoprotein(a) with the angiographic and clinical presentation of coronary artery disease. J. Am. Coll. Cardiol. 83(4), 583-585 (1999). (Pubitemid 29097960)
37. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Metα-analysis of prospective studies. Circulation 102(10), 1082-1085 (2000).
38. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. Clin. Chem. 49(11), 1785-1796 (2003). (Pubitemid 37340313)
39. Bennet A, Di Angelantonio E, Erqou S, et al. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch. Int. Med. 168(6), 598-608 (2008). (Pubitemid 351468395)
40. Berglund L, Anuurad E. Role of lipoprotein(a) in cardiovascular disease: current and future perspectives. J. Am. Coll. Cardiol. 52(2), 132-134 (2008).
41. Kamstrup PR, Benn M, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117(2), 176-184 (2008).
42. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J. Lipid Res. 49(10), 2230-2239 (2008).
43. Edelstein C, Pfaffinger D, Hinman J, et al. Lysine-phosphatidylcholine adducts in kringle V impart unique immunological and potential proinflammatory properties to human apolipoprotein(a). J. Biol. Chem. 278(52), 52841-52847 (2003). (Pubitemid 38035883)
44. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler. Thromb. Vasc. Biol. 27(8), 1788-1795 (2007). (Pubitemid 47207175)
45. Berg K, Dahlen G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein level predicts survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin. Genet. 52(5), 254-261 (1997). (Pubitemid 28068613)
46. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein(a). Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix. J. Clin. Invest. 100(4), 867-874 (1997). (Pubitemid 27371705)
47. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein(a), and risk of fatal and nonfatal coronary events. J. Am. Coll. Cardiol. 56(12), 946-955 (2010).
48. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N. Engl. J. Med. 353(1), 46-57 (2005). (Pubitemid 41007806)
49. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 119(13), 1711-1719 (2009).
50. Mallat Z, Lambeau G, Tedgui A. Lipoprotein-associated and secreted phospholipases A in cardiovascular disease: roles as biological effectors and biomarkers. Circulation 122(21), 2183-2200 (2010).
51. Serruys PW, Garciα-Garcia HM, Buszman P, et al. Effects of the direct lipoprotein-associated phospholipase A2 inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118(11), 1172-1182 (2008).
52. Rosenson RS, Hislop C, Elliott M, Stasiv Y, Goulder M, Waters D. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. J. Am. Coll. Cardiol. 56(14), 1079-1088 (2010).
53. Ehara S, Ueda M, Naruko T, et al. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103(15), 1955-1960 (2001). (Pubitemid 32322222)
54. Holvoet P, Lee DH, Steffes M, Gross M, Jacobs DR Jr: Association between circulating oxidized low-density lipoprotein and incidence of the metabolic syndrome. JAMA 299(19), 2287-2293 (2008). (Pubitemid 351724395)
55. Holvoet P, Vanhaecke J, Janssens S, Van De Werf F, Collen D. Oxidized LDL and malondialdehyde-modified LDL in patients with acute coronary syndromes and stable coronary artery disease. Circulation 98, 1487-1494 (1998). (Pubitemid 28481664)
56. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119(17), 2408-2416 (2009).
57. Arai K, Luke MM, Koschinsky ML, et al. The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis 209(2), 498-503 (2010).
58. Ahmadi N, Tsimikas S, Hajsadeghi F, et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am. J. Cardiol. 105(4), 459-466 (2010).
59. Tsimikas S, Aikawa M, Miller FJ Jr., et al. Increased plasma oxidized phospholipid:apolipoprotein B-100 ratio with concomitant depletion of oxidized phospholipids from atherosclerotic lesions after dietary lipid-lowering: a potential biomarker of early atherosclerosis regression. Arterioscler. Thromb. Vasc. Biol. 27(1), 175-181 (2007). (Pubitemid 46360396)
60. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J. Am. Coll. Cardiol. 51(17), 1653-1662 (2008). (Pubitemid 351626406)
61. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J. Am. Coll. Cardiol. 47(9), 1803-1810 (2006).
62. Silaste ML, Rantala M, Alfthan G, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler. Thromb. Vasc. Biol. 24(3), 498-503 (2004). (Pubitemid 38326144)
63. Budoff MJ, Ahmadi N, Gul KM, et al. Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev. Med. 49(2-3), 101-107 (2009).
64. Faghihnia N, Tsimikas S, Miller ER, Witztum JL, Krauss RM. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J. Lipid Res. 51(11), 3324-3330 (2010).
65. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J. Am. Coll. Cardiol. 52(1), 24-32 (2008). (Pubitemid 351852928)
66. Merki E, Graham MJ, Mullick AE, et al. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118(7), 743-753 (2008).
67. Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein(a) in transgenic mice. J. Am. Coll. Cardiol. 57(15), 1611-1621 (2011).
68. Wu R, De Faire U, Lemne C, Witztum JL, Frostegard J. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 33(1), 53-59 (1999). (Pubitemid 29061841)
69. Penny WF, Ben-Yehuda O, Kuroe K, et al. Improvement of coronary artery endothelial dysfunction with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasmα-oxidized low density lipoprotein. J. Am. Coll. Cardiol. 37(3), 766-774 (2001). (Pubitemid 32202443)
70. Segev A, Strauss BH, Witztum JL, Lau HK, Tsimikas S. Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. Am. Heart J. 150(5), 1007-1014 (2005). (Pubitemid 41607788)
71. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 110(11), 1406-1412 (2004). (Pubitemid 39238018)
72. Fraley AE, Schwartz GG, Olsson AG, et al. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: results from the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial. J. Am. Coll. Cardiol. 53(23), 2186-2196 (2009).
73. Bossola M, Tazza L, Merki E, et al. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis. Blood Purif. 25(5-6), 457-465 (2007). (Pubitemid 351194889)
74. Choi SH, Harkewicz R, Lee JH, et al. Lipoprotein accumulation in macrophages via Toll-like receptor-4-dependent fluid phase uptake. Circ Res 104(12), 1355-1363 (2009).
75. Rahaman SO, Lennon DJ, Febbraio M, Podrez EA, Hazen SL, Silverstein RL. A CD36-dependent signaling cascade is necessary for macrophage foam cell formation. Cell Metab. 4(3), 211-221 (2006). (Pubitemid 44283954)